Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
China’s Shanghai RAAS (SHE: 002252) announced that its candidate SR604 has been included by the...
Company
Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab,...
Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that it has initiated a Phase I...
Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent
Johnson & Johnson MedTech and Jiangsu CED Medical Technology Co., Ltd. (“CED Medical”) have signed...
CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China
CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an...
Ocumension Therapeutics Completes First-Patient Enrollment of OT-202 Phase III Trial for Dry Eye Disease in China
Ocumension Therapeutics (HKG: 1477) announced that OT-202, the company’s first-in-class candidate for the treatment of...
Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform
Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of...
Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug
China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million...
WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies
WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE’s...
Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a...
Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400...
Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand...
Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...
Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...
Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code:...
Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license...
HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for...
AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital...
Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Livzon Pharmaceutical (HKG: 1513) announced that lecankitug, jointly developed with Beijing Kanova Biopharma, has been...
TYK Medicines’ Asandeutertinib Wins NMPA Conditional Approval for EGFR-Mutant NSCLC with CNS Metastases
TYK Medicines (HKG: 2410) announced that its independently developed next-generation EGFR-TKI, asandeutertinib (TY-9591), has received...